Astria Therapeutics, Inc.
ATXS
$5.17
-$0.04-0.77%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 34.48% | 37.75% | 44.46% | 42.61% | 30.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.46% | 59.96% | 66.79% | 52.06% | 26.78% |
| Operating Income | -64.46% | -59.96% | -66.79% | -52.06% | -26.78% |
| Income Before Tax | -29.32% | -82.75% | -90.23% | -71.14% | -40.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.32% | -82.75% | -90.23% | -71.14% | -40.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.32% | -82.75% | -90.23% | -71.14% | -40.63% |
| EBIT | -64.46% | -59.96% | -66.79% | -52.06% | -26.78% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 28.48% | 4.86% | 5.73% | 18.73% | 35.57% |
| Normalized Basic EPS | 12.99% | 23.78% | 22.78% | 33.30% | 47.03% |
| EPS Diluted | 28.48% | 4.86% | 5.73% | 18.73% | 35.57% |
| Normalized Diluted EPS | 12.99% | 23.78% | 22.78% | 33.30% | 47.03% |
| Average Basic Shares Outstanding | 86.42% | 98.28% | 96.66% | 98.09% | 107.05% |
| Average Diluted Shares Outstanding | 86.42% | 98.28% | 96.66% | 98.09% | 107.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |